Cost-effectiveness of Helicobacter pylori “test and treat” for patients with typical reflux symptoms in a population with a high prevalence of H. pylori infection: A Markov model analysis

References

• Anonymous. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44 Suppl 2:S1–16.
   PubMedGoogle Scholar
• Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastroesophageal reflux disease. Lancet 1990; 335: 205–8
   PubMed Web of Science ®Google Scholar
• Quigley EM. 24-h pH monitoring for gastroesophageal reflux disease: already standard but not yet gold?. Am J Gastroenterol 1992; 87: 1071–5
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996; 110: 1982–96
   PubMed Web of Science ®Google Scholar
• Wu JC, Chan FK, Ching JY, Leung WK, Lee YT, Sung JJ. Empirical treatment based on “typical” reflux symptoms is inappropriate in a population with a high prevalence of H. pylori infection. Gastrointest Endosc 2002; 55: 461–5
   PubMed Web of Science ®Google Scholar
• Wu JC, Chan FK, Wong SK, Lee YT, Leung WK, Sung JJ. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux esophagitis. Aliment Pharmacol Ther 2002; 16: 545–52
   PubMed Web of Science ®Google Scholar
• Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 45–51
   PubMed Web of Science ®Google Scholar
• Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor Pantoprazole. Gastroenterology 1999; 117: 11–6
   PubMed Web of Science ®Google Scholar
• Verdu EF, Amstrong D, Fraser Re, Viani F, Idstrom JP, Cederberg C, et al. Effect of Heliobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539–43
   PubMed Web of Science ®Google Scholar
• Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Dorta G, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995; 37: 743–8
   PubMed Web of Science ®Google Scholar
• Wu JC, Chan FK, Ching JY, Leung WK, Hui Y, Leong R, et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, practice trial. Gut 2004; 53: 174–9
   PubMed Web of Science ®Google Scholar
• Raghunath A, Hungin APS, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. Br Med J. 2003; 326: 737–13
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Pajares JM. 13C-urea breath test in the diagnosis of Helicobacter pylori infection: a critical review [review article]. Aliment Pharmacol Ther 2004; 20: 1001–17
   PubMed Web of Science ®Google Scholar
• Sung JJ, Chung SC, Ling TK, Suen R, Leung VK, Lau JY, et al. Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcer. Dig Dis Sci 1996; 41: 453–7
   PubMed Web of Science ®Google Scholar
• Sung JJ, Leung VK, Chung SC, Ling TK, Suen R, Cheng AF, et al. Triple therapy with sucralfate, tetracycline and metronidazole for Helicobacter pylori-associated duodenal ulcers. Am J Gastroenterol 1995; 90: 1424–7
   PubMed Web of Science ®Google Scholar
• Hosking SW, Ling TK, Chung SC, Yung MY, Cheng AF, Sung JJ, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomized controlled trial. Lancet 1994; 343: 508–10
   PubMed Web of Science ®Google Scholar
• Sung JJ, Chung SC, Ling TK, Yung MY, Leung VK, Ng EK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995; 332: 139–42
   PubMed Web of Science ®Google Scholar
• Sung JJ, Leung WK, Ling TK, Yung MY, Chan FK, Lee YT, et al. One-week use of ranitidine bismuth citrate, practice in and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. Aliment Pharmacol Therapeut 1998; 12: 725–30
   PubMed Web of Science ®Google Scholar
• Kung NN, Sung JJ, Yuen NW, Ng PW, Wong KC, Chung EC, et al. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy. Am J Gastroenterol 1997; 92: 438–41
   PubMed Web of Science ®Google Scholar
• Kung NN, Sung JJ, Yuen NW, Li TH, Ng PW, Lai WM, et al. One-week rantidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial. Am J Gastroenterol 1999; 94: 721–4
   PubMed Web of Science ®Google Scholar
• Festen HP, Schenk E, Tan G, Snel P, Nelis F. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. Am J Gastroenterol 1999; 94: 931–6
   PubMed Web of Science ®Google Scholar
• Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams daily, omeprazole 20 milligrams daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy of symptoms of gastroesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 9065–73
   Web of Science ®Google Scholar
• Bate CM, Green JRB, Axon ATR. Omeprazole is more effective than cimetidine for the relief of all grades of gastroesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic esophagitis. Aliment Pharmacol Ther 1997; 11: 755–63
   PubMed Web of Science ®Google Scholar
• Kaplan-Nachlis B, Spiegler GE, Zodet MW. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000; 9: 624–30
   PubMedGoogle Scholar
• Jasen J, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux esophagitis. Aliment Pharmacol Ther 1999; 13: 1611–20
   PubMed Web of Science ®Google Scholar
• Bardhan KD, Hawkey GJ, Long RG, Morgan AG, Wormsley KG, Moules IK, et al. Lansoprazole versus ranitidine for the treatment of reflux esophagitis. Aliment Pharmacol Ther 1995; 9: 145–51
   PubMed Web of Science ®Google Scholar
• Farley A, Wruble LD, Humphries TJ. Rabeprazole versus rantidine for the treatment of erosive gastroesophageal refux disease: a double-blind randomized clinical trial. Rabeprazole Study Group. Am J Gastroenterol 2000; 95: 1894–9
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastroesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765–73
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249–58
   PubMed Web of Science ®Google Scholar
• Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL, et al. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 479–85
   PubMed Web of Science ®Google Scholar
• Kinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161–7
   PubMed Web of Science ®Google Scholar
• Escourrou J, Deprez P, Saggioro A, Geldof H, Fischer R, Maier C, et al. A maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Aliment Pharmacol Ther 1999; 13: 1481–91
   PubMed Web of Science ®Google Scholar
• Bate CM, Booth SN, Crowe JP, Mountford RA, Keeling PW, Hepworth-Jones B, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 1995; 36: 492–8
   PubMed Web of Science ®Google Scholar
• Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Haber M. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. Am J Gastroenterol 1996; 91: 1758–65
   PubMed Web of Science ®Google Scholar
• Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997; 11: 365–72
   PubMed Web of Science ®Google Scholar
• Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. Dig Dis Sci 2000; 45: 845–53
   PubMed Web of Science ®Google Scholar
• Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927–35
   PubMed Web of Science ®Google Scholar
• Thijs JC, Kuipers EJ, van Zwet AA, Pena S, de Graff J. Treatment of Helicobacter pylori infections. Q J Med 1995; 88: 369–89
   Google Scholar
• Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98: 2621–6
   PubMed Web of Science ®Google Scholar
• Harvey RF, Lan JA, Murray LJ, Harvey IM, Donovan JL, Nair P. Randomize controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol Helicobacter project. Br Med J 2004; 328: 1417–9
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck RJ. Markov models in medical decision making: a practice guide. Med Decision Making 1993; 13: 322–38
   PubMed Web of Science ®Google Scholar
• Graham DY. Ulcer complications and their nonoperative treatment. Gastrointestinal disease5th ed, M Sleisenger, J Fordtran. WB Saunders, Philadelphia 1993; 698–712
   Google Scholar
• You JHS, Lee ACM, Wong SCY, Chan FKL. Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2003; 17: 785–92
   PubMed Web of Science ®Google Scholar
• You JHS, Lee KKC, Chan TYK, Lau WH, Chan FKL. Arthritis treatment in Hong Kong: cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Aliment Pharmacol Ther 2002; 16: 2089–96
   PubMed Web of Science ®Google Scholar
• Farkkila M, Sarna S, Valtonen V, Sipponen P. Does the “test-and-treat” strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. Scand J Gastroenterol 2004; 39: 327–35
   PubMed Web of Science ®Google Scholar
• Rich M, Scheiman JM, Tierney W, Fendrick AM. Is upper gastrointestinal radiography a cost-effective alternative to a Helicobacter pylori “test and treat” strategy for patients with suspected peptic ulcer disease?. Am J Gastroenterol 2000; 95: 651–8
   PubMed Web of Science ®Google Scholar
• Ladabaum C, Chey WD, Scheiman JM, Fendrick AM. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis. Aliment Pharmocol Therapeut 2002; 16: 1491–501
   PubMed Web of Science ®Google Scholar
• Fendrick AM, Shaw M, Schachtel B, Allgood L, Allgood L, Grender J, et al. Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol 2004; 2: 17–21
   PubMed Web of Science ®Google Scholar
• Wong WM, Lam SK, Hui WM, et al. Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese: prevalence and spectrum of the disease. Aliment Pharmacol Ther 2002; 16: 2037–42
   PubMed Web of Science ®Google Scholar
• Rajendra S, Kutty K, Karim N. Ethnic differences in the prevalence of endoscopic esophagitis and Barrett's esophagus: the long and short of it all. Dig Dis Sci 2004; 49: 237–42
   PubMed Web of Science ®Google Scholar